Back to News
Market Impact: 0.4
Abbott To Pay $385 Mln To Resolve Claims Related To 2022 Infant Formula Recall
Source: Nasdaq
Legal & LitigationRegulation & LegislationHealthcare & Biotech
Abbott Laboratories reached a $385 million agreement with the U.S. Department of Justice to resolve claims tied to manufacturing practices and its 2022 powdered infant-formula recall at the Sturgis, Michigan facility. The settlement creates a material legal and reputational overhang for Abbott, though it resolves a significant outstanding liability related to the recall.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
ABT-0.85
More News
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- US Senate crypto bill collapses in blow to industry
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Factbox-How AI leaders and world governments react to ’AI doom’ fears
- ‘The end of the keyboard is near’: Christian Klein predicts voice translation will be the next workplace advantage
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown